newsfilter
← Latest News
PR Newswire·

Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability

IOVAMRKLLYJNJ
  • The global cancer therapy landscape is shifting toward precision nanomedicine delivery systems to improve bioavailability, reduce toxicity, and enhance patient outcomes.
  • Oncotelic Therapeutics (OTCQB: OTLC) leads this evolution with its proprietary Deciparticle platform, which uses modular nanocarriers to increase drug bioavailability from 10–20% to 80–100%.
  • Sapu-003, an injectible Deciparticle Everolimus formulation, has entered first-in-human clinical trials in Australia, validating the platform's safety and manufacturing standards.
  • Three abstracts regarding Sapu-003 were accepted for presentation at the 2025 San Antonio Breast Cancer Symposium (SABCS) in December.
  • The nanomedicine market is projected to exceed $500 billion by 2032, driven primarily by delivery innovation rather than new molecule discovery.
  • Deciparticle technology aims to re-engineer existing drugs like Everolimus to allow lower dosing, reduced systemic toxicity, and faster clinical development timelines.
  • Iovance Biotherapeutics received Health Canada approval for Amtagvi for unresectable or metastatic melanoma.
  • Merck & Co. received FDA priority review for KEYTRUDA combinations for muscle-invasive bladder cancer, with an action date set for April 7, 2026.
  • Eli Lilly reported that two years of adjuvant Verzenio plus endocrine therapy reduced the risk of death by 15.8% in high-risk early breast cancer patients.
  • Johnson & Johnson presented data showing that INLEXZO plus cetrelimab achieved clinically meaningful response rates in patients with muscle-invasive bladder cancer ineligible for platinum-based chemotherapy.
  • Competitors in the broader oncology space include Iovance Biotherapeutics, Merck & Co., Eli Lilly, and Johnson & Johnson.